Imugene (ASX:IMU)The cancer treatment company is developing...

Imugene (ASX:IMU)

The cancer treatment company is developing several treatments that seek to harness and promote the body’s immune system against cancerous tumours.

Among its portfolio IMU has developed a B-cell immunotherapy called HER-Vaxx to address tumours characterised by heightened expression of the HER-2/neu receptor including gastric, breast, ovarian, lung, and pancreatic cancers.

Pachacz says IMU is on the record as looking at doing a licensing deal for its HER-Vaxx technology.

IMU has done positive Phase 2 studies for the technology in gastric cancer.

“Rather than having antibodies injected, they stimulate and train the immune system through a vaccine to produce its own antibodies,” he says.

“They’ve gone on the record as saying they not looking at conducting Phase 3 studies but more looking at licensing at the end of Phase 2 so investors should look out for a deal in the future.”